While every death from Hepatitis C is a human tragedy millions of people suffer chronic fatigue from the illness, often enduring decades of suffering.

Considering so BEACON proudly introduced the combination of two blockbuster drugs to treat hepatitis C. Darvoni provides a convenient once a day single tablet formulation containing Sofosbuvir 400 mg + Daclatasvir 60 mg that is suitable to treat all genotypes of Hepatitis C.

The once-daily tablet, called Darvoni, provides ease of administration and no fear of injection.

The high cost of branded direct-acting antivirals has led to rationing of treatment, slow drug approvals and refusal of insurance coverage in many countries. People unable to obtain hepatitis C treatment through existing health care have turned in desperation to the BEACON for help in obtaining generic versions of sofosbuvir and daclatasvir.

A full course of Darvoni tablet is available at a rate of a single branded medication. Now the question is about therapeutic equivalence?

A recent study has been presented by Dr. James Freeman (Owner of GP2U Telehealth) at International Liver Congress-Barcelona’ 2016 (organized by EASL) on the therapeutic equivalence of generic medicine with Branded formulations. Results of this study are the solid evidence of Darvoni’s therapeutic equivalence against branded versions. Apart from therapeutic equivalence, Darvoni shows similar side effects and relapse rate in comparison to branded versions.

For more information about Darvoni tablet, please visit www.darvoni.com